Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today

·2-min read
Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today

Infinity Pharmaceuticals (NASDAQ: INFI) got off to a market-beating start this week as its shares zoomed 3.8% higher Monday, on the back of new analyst coverage that made an extremely bullish case for investing in the biotech. H.C. Wainwright's Michael King Jr. is the prominent new Infinity bull. King points out that the company's lead pipeline candidate, the cancer treatment eganelisib, "has shown compelling activity both as a single agent as well as in combination with commonly used immune checkpoint inhibitors."

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting